- Home
- ED vs RVMD Comparison
ED vs RVMD Comparison
Compare ED & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ED | RVMD |
|---|---|---|
| Founded | 1884 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 40.3B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ED | RVMD |
|---|---|---|
| Price | $115.62 | $188.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 25 |
| Target Price | $108.66 | ★ $257.80 |
| AVG Volume (30 Days) | 1.7M | ★ 2.1M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 7.63 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $16,918,000,000.00 | N/A |
| Revenue This Year | $3.83 | N/A |
| Revenue Next Year | $4.93 | $558.43 |
| P/E Ratio | $45.73 | ★ N/A |
| Revenue Growth | ★ 10.89 | N/A |
| 52 Week Low | $94.96 | $55.40 |
| 52 Week High | $116.27 | $224.31 |
Technical Indicators
Market Signals| Indicator | ED | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 71.43 | 44.61 |
| Support Level | $109.12 | $188.18 |
| Resistance Level | N/A | $194.19 |
| Average True Range (ATR) | 2.03 | 10.41 |
| MACD | 1.07 | -0.21 |
| Stochastic Oscillator | 93.04 | 37.97 |
Price Performance
Historical ComparisonAbout ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York, including New York City, and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.